Lung Cancer News

Erminia Massarelli, MD, PhD, MS, co-director of the lung cancer and thoracic oncology program, and associate professor in the department of medical oncology and therapeutics research at City of Hope Cancer Center in Duarte, California, spoke with Healio about treatments in the pipeline for EGFR-mutated lung cancer.

Patients with rheumatoid arthritis who received tofacitinib demonstrated a greater risk for major adverse cardiovascular events and cancer than those treated with TNF inhibitors, according to data in The New England Journal of Medicine.

The addition of sugemalimab to first-line chemotherapy significantly prolonged OS among patients with stage IV non-small cell lung cancer, according to topline data released by the agent’s manufacturer.

HF may be associated with cancer incidence as well as risk for cancer-related mortality, especially among individuals aged 50 to 70 years, according to new data published in JACC: CardioOncology.

A blood test based on a four-marker protein panel combined with an independent risk prediction model that accounts for smoking history significantly improved patient selection for lung cancer screening, according to study results.

The FDA cleared an investigational new drug application for FT536, a chimeric antigen receptor natural killer cell therapy designed to treat adults with certain relapsed or refractory solid tumors.

An increasing percentage of lung cancer cases are being diagnosed at an earlier stage, according to a new report from American Cancer Society.

The concept of patients continuing to exercise while undergoing active cancer treatment is not new, but it may need reinforcing.

Pembrolizumab extended DFS compared with placebo as adjuvant treatment for patients with stage IB to stage IIIA non-small cell lung cancer, according to topline data released by the agent’s manufacturer.

The FDA granted breakthrough therapy designation to telisotuzumab vedotin for treatment of certain patients with non-small cell lung cancer.